PULMOPHARMA ApS: Financial statements 2019
CVR: 36428023
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
PULMOPHARMA ApS (CVR 36428023) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -8,735 and a net result of DKK -25,905 compared with DKK -223,907 the year before. Equity in the 2019 report amounted to DKK -376,224.
- Gross Profit
- DKK -8,735
- Profit/Loss
- DKK -25,905
- Equity
- DKK -376,224
- Total Assets
- DKK 79,880
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -9 t. | -26 t. | -376 t. | - |
| 2018 | - | -292 t. | -224 t. | -350 t. | - |
| 2017 | - | -120 t. | -123 t. | -126 t. | - |
| 2016 | - | 0 | 0 | -3 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
PULMOPHARMA ApS has published its annual report for 2018. Gross profit came to DKK -292,381, and the net result was DKK -223,907.
About PULMOPHARMA ApS
PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PULMOPHARMA IVS. The management consists of Dan Mønster Nielsen. The board consists of Torben Ballegaard Sørensen (chair), Dan Mønster Nielsen, Per Bendix Jeppesen and Peter Frithjof Bang. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.